E-cadherin involved in inactivation of WNT/β-catenin signalling in urothelial carcinoma and normal urothelial cells by Thievessen, I et al.
E-cadherin involved in inactivation of WNT/b-catenin signalling in
urothelial carcinoma and normal urothelial cells
I Thievessen
1,2, H-H Seifert
1, S Swiatkowski
1, AR Florl
1 and WA Schulz*,1
1Urologische Klinik, Heinrich-Heine-Universita ¨t, Du ¨sseldorf, Germany
Constitutive activation of WNT signalling through b-catenin, which leads to increased transcription of TCF/b-catenin target genes, is
crucial in the development of many human tumour types including colorectal carcinoma and hepatoma. Its role in urothelial cancer
(TCC) is unclear, since typical activating mutations are not found. We therefore determined the activity of a b-catenin/TCF-
dependent promoter in proliferating normal uroepithelial cells and seven TCC cell lines, using a hepatoma line with oncogenic
b-catenin as a control. Neither normal urothelial cells nor TCC lines exhibited activity under normal growth conditions. In normal
cells and 5/7 TCC lines, even transfection of activated b-catenin did not restore promoter activity, suggesting repression of b-catenin/
TCF activity. TCF mRNAs and total b-catenin protein levels did not differ qualitatively between inducible and noninducible cell lines,
but E-cadherin expression was lacking or low in inducible TCC lines. In these, cotransfection of E-cadherin diminished activation of
the TCF-dependent promoter by b-catenin. Our results make constitutive WNT/b-catenin signalling in TCC appear unlikely, thereby
explaining the lack of reported mutations. However, decreased E-cadherin expression occurring in many TCC, often as a
consequence of promoter hypermethylation, may confer inappropriate responsiveness to WNT factors.
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Inappropriate or autonomous activation of intracellular signal
transduction pathways is a major cause for increased proliferation
of tumour cells. In several major human cancers, the WNT/b-
catenin signal transduction pathway is constitutively activated,
regularly in colon carcinoma and hepatoma, and with considerable
frequency in melanoma, mammary carcinoma, medulloblastoma
and in some cases of renal, ovarian, thyroid and prostate
carcinomas (Polakis, 2000). In normal tissues, this pathway is
crucial for regulation of cell growth and differentiation, from
embryonic tissue patterning to adult tissue homeostasis. In
particular, WNT signalling may be important for the maintenance
of epithelial stem cell compartments (Taipale and Beachy, 2001).
The WNT/b-catenin pathway elicits activation of specific target
genes including the proto-oncogene c-MYC, the cell cycle activator
CCND1 (CyclinD1) and the metalloprotease gene MMP7 (Crawford
et al, 1999) (see http://www.stanford.edu/Brnusse/wntwin-
dow.html for a list of target genes). In the absence of activating
WNT signals, b-catenin is phosphorylated by a multiprotein
complex containing GSK3b, the tumour suppressors APC and
axin/conductin. Phosphorylated b-catenin is recognised by a
ubiquitin–ligase complex with b-TrCP as the crucial component,
ubiquitinylated and degraded by the proteasome. Binding of an
activating WNT factor to the Frizzled receptor leads to the
inactivation of GSK3b via activation of Dishevelled and GBP/FRAT
and thus to stabilisation of b-catenin, which accumulates in the
cytoplasm, translocates into the nucleus and heterodimerises with
TCF/LEF transcription factors to activate target genes containing
specific TCF binding sites in their promoters. Constitutive
activation of WNT/b-catenin signalling in cancer is caused by a
variety of mutations in various components of the pathway,
leading either to inactivation of APC, axin/conductin or b-TrCP or
to oncogenic activation of b-catenin. In addition, recent evidence
suggests that the activity of the pathway may also be influenced by
further factors, notably by the status of the E-cadherin cell
adhesion protein (Stockinger et al, 2001). Whichever mechanism
causes constitutive activation of the WNT/b-catenin pathway, its
activity is reflected in increased transcription of genes containing
TCF binding sites.
While the importance of WNT/b-catenin signalling is well
established in many human carcinomas, its role in transitional cell
bladder carcinoma (TCC) is unclear. WNT/b-catenin signalling is
implicated in urothelial development. Expression of Wnt2b in
mesenchymal renal cells induces ureter branching in the murine
foetus (Lin et al, 2001). In the human foetus, WNT11 is expressed
in the tips of the ureter buds and other urogenital tissues (Lako
et al, 1998). Thus, a function of WNT/b-catenin signalling in adult
urothelial tissue homeostasis is conceivable. Indeed, differences in
WNT7B expression have been reported between normal urothe-
lium, superficial and invasive bladder carcinomas (Bui et al, 1998).
However, mutations typically responsible for deregulated b-
catenin/TCF activity in other tumours, that is, in APC, AXIN,
BTRC and CTNNB1, have not been found in TCC to date (Stoehr
et al, 2002). This might mean that mutations are rare or absent in
this cancer type, that they are difficult to detect, that they occur at
unusual sites in the above genes or that they affect different
components of the pathway than in other cancers. This is, of Received 18 October 2002; accepted 26 March 2003
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scourse, difficult to ascertain. Two established changes potentially
affecting the activity of this pathway in TCC are hypermethylation
of the APC promoter and diminished expression of E-cadherin,
caused by CDH1 hypermethylation or mutation. These changes
have been reported to occur with moderate (APC) or high
frequency (CDH1) in advanced TCC and could conceivably lead
to increased b-catenin/TCF activity and proliferation in TCC
(Maruyama et al, 2001; Ribeiro-Filho et al, 2002).
To circumvent the vagaries associated with mutation detection
in multiple candidate genes and to determine the significance of
reported changes in CDH1 and APC in TCC, we have determined
WNT/b-catenin activity and inducibility in TCC cell lines and in
cultured normal uroepithelial cells (NUEC). Transitional cell
bladder carcinoma lines harbour genetic changes and gene
expression patterns typical of advanced TCC and provide a well-
characterised and established experimental system to study
properties of this tumour. Normal uroepithelial cells can be
maintained in primary cultures, where they proliferate sponta-
neously or stimulated by external growth factors such as EGF.
Furthermore, we analysed the expression of b-catenin, APC and E-
cadherin at the protein level and expression of TCFs at the mRNA
level. The effect of E-cadherin was investigated in more detail.
Overall, our data suggest that proliferation of TCC does not
depend on activity of the WNT/b-catenin pathway, which instead
appears to be generally repressed. E-cadherin may act as a buffer
for b-catenin activity in urothelial cells and its loss in TCC may
not only affect cell adhesion, but also sensitivity towards WNT
factors.
MATERIALS AND METHODS
Cell lines and culture
The bladder carcinoma cell lines, VMCub1, VMCub2, SW1710, SD,
HT1376, 5637 and BFTC905, obtained from the DSMZ, Braunsch-
weig, Germany, were cultured in Dulbecco’s minimal essential
medium (Gibco Life Technologies, Karlsruhe, Germany), supple-
mented with 15% fetal calf serum and 100mg/ml penicillin/
streptomycin as described (Grimm et al, 1995). The hepatoma
cell line HepG2, used as positive control because of its oncogenic
b-catenin mutation, was cultured as described (Schulz et al, 1988).
Ureters from nephrectomy patients were used to prepare NUEC as
described by Southgate et al (1994). These were routinely
maintained in keratinocyte serum-free medium (KSFM, Gibco
Life Technologies) supplemented with 50mg/ml bovine pituitary
extract (BPE), 5ng/ml epidermal growth factor (EGF) and 30ng/ml
cholera toxin. After the first passage, they were used for
experiments as described (Swiatkowski et al, 2002).
Plasmids
The reporter plasmids pTopFlash and pFopFlash, containing wild-
type or mutant TCF binding sites, respectively, in front of the HSV
thymidine kinase minimal promoter driving the Photinus pyralis
luciferase gene, were purchased from Upstate Biotechnology (c/o
Biomol, Hamburg, Germany). The Renilla reniformis luciferase
reporter plasmid, pTKRL, used as internal control for transfection
efficiencies, and the negative control vector pGL3 were purchased
from Promega, Mannheim, Germany. pLINEluc, constructed by
insertion of bps  193 to þ661 from the active LINE-1 element
L1.2B into pGL3 (Steinhoff et al, 2002) was used as positive
control. The following expression plasmids were used: pbcat,
kindly donated by Dr H Clevers, Utrecht, NL, contains human b-
catenin cDNA with an activating S33Y mutation driven by the
strong CMV promoter. pEGFP-UM permits expression of murine
E-cadherin cDNA, kindly provided by Dr R Kemler, Freiburg,
Germany, from the CMV promoter.
Transfections and reporter gene assays
Cells were grown in six-well plates to 30% confluence. Transient
transfection was carried out using FuGene/DMEM (Roche,
Mannheim, Germany) at a 1:25 dilution. Per well, 1mg of reporter
plasmid, 0.5mg of each expression plasmid and 0.15mg pTKRL
were transfected. At 80% confluence, cells were lysed and luciferase
activity was measured using the Dual Luciferase Reporter Assay
System (Promega, Heidelberg, Germany) as recommended by the
manufacturer. Each experiment was repeated with at least five
independent passages or cultures.
Western blotting
Cells were grown in 75cm
2 tissue culture flasks to 80% confluence
and lysed for 1h on ice in modified RIPA-buffer (50mM Tris, pH
7.2, 150mM NaCl, 40mM NaF, 5mM EGTA, 5mM EDTA, 1mM
sodium orthovanadate, 1% nonidet P-40, 0.1% sodium dodecyl-
sulphate, 0.1% sodium deoxycholate, 10mg/ml phenylmethyl-
sulphonylfluoride). Protein amounts were quantified by the
Bradford method. For SDS–polyacrylamide gel electrophoresis
(10% polyacrylamide for b-catenin and E-cadherin, 5% for APC),
10mg of protein were used and subsequently transferred to an
Immobilon-P membrane (Millipore Corp., Bedford, MA, USA).
After blocking in 10% nonfat milk powder in PBS overnight at 41C,
membranes were incubated for 1h at room temperature with
primary antibodies at the following dilutions: anti-b-catenin (BD
Transduction Laboratories, Heidelberg, Germany) at 1:1500, anti-
E-cadherin (Santa Cruz Biotechnology, CA, USA) at 1:1000, anti-
APC (Upstate Biotechnology, c/o Biomol, Hamburg, Germany) at
1:500 and anti-a-tubulin (Sigma, St Louis, MO, USA) at 1:5000.
Incubation with HRP-conjugated rabbit anti-mouse secondary
antibody (Santa Cruz Biotechnology) at 1:5000 was carried out at
room temperature for 1h, followed by luminescence detection with
the ECL-Kit (Amersham-Pharmacia, Freiburg, Germany).
RNA isolation and RT–PCR
Total mRNA was isolated from cultures grown to 80% confluence,
using the RNeasy
s Midi Kit (Qiagen, Hilden, Germany). After
quantification, mRNA was transcribed into first-strand cDNA
using AMV-RT (Promega, Mannheim, Germany). Polymerase
chain reactions were carried out in a total 20ml volume containing
1  PCR-buffer (Biometra, Go ¨ttingen, Germany), 150mM of each
nucleotide, 10 pmol of each primer, 1U of Taq polymerase
(Biometra) with 2% (CTNNB1), 3% (TCF1), 2% (TCF4) and 2.5%
(hAES) formamide added. Each PCR cycle consisted of 30s
denaturing at 951C, 30s at the annealing temperature and 1min at
721C. Each initial denaturation was performed for 5min at 951C
and each final extension for 7min. A total of 25 cycles were
performed for CTNNB1 at 571C annealing temperature, 34 cycles at
591C for TCF1, 35 cycles at 581C for LEF1, 31 cycles at 591C for
TCF3, 29 cycles at 561C for TCF4, and for hAES, 36 cycles at 591C.
Primer pairs were selected according to Iwao et al (1998) for
CTNNB1, Duval et al (2000) for TCF4 and Brantjes et al (2001) for
TCF1, LEF1, TCF3 and hAES. GAPDH, with primers added to the
mixture for the last 19 cycles, served as an internal control.
Polymerase chain reaction products were separated by agarose gel
electrophoresis (2%) and visualised by ethidium bromide staining.
DNA extraction and methylation analysis
High molecular weight genomic DNA from cell lines was isolated
using the blood and cell culture DNA kit (Qiagen, Hilden,
Germany). MS-PCR was performed essentially as described by
Herman et al (1996). In short, 1mg DNA from each cell line was
bisulphite-treated with the CpGenome DNA modification kit
(Oncor, Heidelberg, Germany). Aliquots from the reaction mixture
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pairs from the CDH1 and the APC gene promoter regions specific
for converted, that is unmethylated, or unconverted, that is
methylated, DNA using the conditions specified in Herman et al
(1996) and Virmani et al (2001). Polymerase chain reaction
conditions were as follows: template DNA (100ng) was amplified
in a total volume of 50ml containing 150mM of each dNTP, 1.5mM
MgCl2, 15pmol of each primer, and 1.25U of HotStar Taq
polymerase (Qiagen, Hilden, Germany). Following initial dena-
turation at 941C for 15min, 35 cycles of 30s at 951C, 30s at Tm, and
45s at 721C were performed. All reactions included a final
elongation step at 721C for 10min.
RESULTS
Properties of cell lines used
Some important properties of the TCC lines used in this study are
compiled in Table 1, including APC and CDH1 hypermethylation
status, which were newly determined. By MS-PCR, all APC alleles
were hypermethylated in HT1376, and one allele of CDH1 was
hypermethylated in SW1710.
Reporter gene analysis of endogenous and inducible
b-catenin/TCF signalling activity
First, endogenous activity of the WNT/b-catenin pathway was
determined in proliferating NUEC and seven TCC lines under
optimal growth conditions. The hepatoma cell line HepG2
harbouring an activating b-catenin mutation was used as a
positive control. The cells were transfected with either pTopFlash
or pFopFlash plasmids. These plasmids are identical but for
mutations in the TCF/b-catenin binding sites in the promoter
driving luciferase expression. The ratio of luciferase expression
from pTopFlash to pFopFlash is an established indicator of
Wnt/b-catenin pathway activity. Differences in transfection
efficiencies were corrected by cotransfection of a Renilla luciferase
plasmid. Plasmids without a promoter (pGL3) or with a cell-type-
independent retrotransposon promoter (pLINEluc) were included
in each experiment as quality controls.
Figure 1A shows the pTopFlash to pFopFlash ratio in seven
TCC-lines, normal urothelial cells and the positive control HepG2.
As expected for a cell line with an activating b-catenin mutation,
HepG2 displayed significant endogenous signalling activity
(12.373.3). In contrast, the ratios found in normal urothelial cells
(0.9670.09) and in the TCC lines (range: 0.6470.20–1.3371.3)
indicate lack of b-catenin/TCF signalling.
Next, we tested whether mutationally activated b-catenin was
able to induce promoter activity from pTopFlash in TCC and
NUEC in cotransfection experiments. Figure 1B displays the ratios
of luciferase activity with vs without b-catenin. Surprisingly, in
normal urothelial cells and four of seven TCC-lines, the ratio did
not differ significantly from 1 with values ranging from 0.270.1 in
normal urothelial cells to 2.472.1 in VMCub1, indicating that
expression of activated b-catenin was not sufficient to increase
transcription from the b-catenin/TCF-dependent promoter. In
contrast, significant induction was observed in the TCC lines
SW1710 (12.772.3) and 5637 (58.7723.8). A slight, but not
statistically significant induction was observed in BFTC905
(4.972.0). The high basal activity in HepG2 was not further
increased by transfected b-catenin, as expected. Cotransfection of
b-catenin did not significantly alter the activity of pFopFlash
(Figure 1C) in any cell type.
Expression of b-catenin
To identify the cause for the different inducibility of the TCC lines
by oncogenic b-catenin, we first compared the expression of
endogenous b-catenin. Qualitative RT-PCR analysis revealed b-
catenin mRNA to be present in all TCC lines and in normal
urothelial cells with only slight differences in expression levels
(Figure 2A). Western blot analysis confirmed that overall b-catenin
expression was also similar in all TCC lines and normal urothelial
cells at the protein level (Figure 2B). Thus, the differences in
inducibility were not due to major differences in b-catenin
expression between inducible and noninducible TCC-lines.
Expression of TCF and hAES mRNA
b-catenin-mediated transcription depends on its interaction in the
nucleus with TCF/LEF transcription factors, which in the absence
of b-catenin act as transcriptional repressors by interacting with
transcriptional corepressors of the Grg/TLE-family. Thus, expres-
sion patterns of TCF/LEF factors and perhaps of TLE factors could
account for the different inducibilities between the TCC lines and
were therefore investigated by RT–PCR analysis. GAPDH served as
internal control. First, we analysed mRNA expression of hTCF1,
hLEF1, hTCF3 and hTCF4. Among these, hTCF1 and hTCF4
mRNAs were found in all TCC lines, normal urothelial cells and
HepG2 (Figure 3A and D). Interestingly, in the inducible TCC lines
Table 1 Properties of TCC lines
TCC line
TP53
mutation
RB
Western blot CDKN2A
APC
methylation
APC
Western blot
CDH1
methylation
E-Cadherin
Western blot
VmCub1 Mutant + Mutant   +   +
Exon 5
VmCub2 Mutant + Deleted   +   
Exon 5
SW1710 Mutant + Deleted   + 7  
Exon 8
SD Mutant + Deleted   +   +
Exon 4
HT1376 Mutant   ++ +   +
Exon 7
5637 Mutant   +   +   7
Exon 8
BFTC905 Wild-type + Deleted   +   +
(MDM2mm)
For each cell line, TP53, RB and CDKN2A status are given as previously described (Steinhoff et al, 2002; Swiatkowski et al, 2002). APC and CDH1 hypermethylation and expression
were determined in the present study as described in the Materials and methods section. Methylation status: + hypermethylated,   no hypermethylation; 7 both
hypermethylated and unmethylated alleles detectable; protein expression: + present;   not detectable; 7 weakly detectable.
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sSW1710 and 5637 hTCF1 expression was slightly, but reproducibly
increased relative to GAPDH (Figure 3A). Expression of hLEF1 was
more heterogeneous (Figure 3B). The TCC lines SW1710, HT1376
and BFT905, normal urothelial cells and HepG2 displayed only
faint bands or lacked hLEF1 expression, which was robustly
detected in VMCub1, VMCub2, SD and 5637. Two bands were
found which correspond to known hLEF1 splice variants (Carlsson
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Figure 1 Basal and inducible activities of a TCF/b-catenin-dependent
promoter in TCC lines and NUEC. The indicated TCC lines, NUEC and
the hepatoma cell line HepG2 (hatched bar) were transfected with
reporter plasmids and luciferase activity was measured 2 days later. All data
are derived from at least five independent triplicate experiments. (A) Basal
activity of a TCF/b-catenin-dependent promoter (contained in pTopFlash)
in TCC lines. Mean7s.d. of the pTopFlash/pFopFlash activity ratio are
shown. The dotted line indicates a ratio of 1 corresponding to lack of
activity. The ratio is significantly different in the HepG2-positive control cell
line (*t-test; Po0.05). (B) Induction of pTopFlash reporter activity by
oncogenic b-catenin. Data are mean7s.d. of the ratio pTopFlashþpbcat/
pTopFlash. The dotted line indicates a ratio of 1 indicating lack of
inducibility. Statistically significant inducibility (*t-test: Po0.05) was
observed in the TCC lines SW1710 and 5637. (C) Effect of oncogenic
b-catenin on activity of the pFopFlash reporter that contains mutated TCF
sites. Data are mean7s.d. of the ratio pFopFlashþpbcat/pFopFlash. The
dotted line indicates a ratio of 1 indicating lack of inducibility. No statistically
significant inducibility was observed.
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Figure 2 Expression of b-catenin in TCC lines and normal uroepithelial
cells. Expression of b-catenin (CTNNB1) was determined in the indicated
TCC lines, NUEC and HepG2 hepatoma cells at the mRNA level (A)b y
RT–PCR using GAPDH for comparison and at the protein level (B) using
a-tubulin for comparison. Control in (A) refers to PCR without cDNA, the
size marker is shown on the right-hand lane. Control in (B) was supplied by
the antibody manufacturer.
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Figure 3 Expression of TCF mRNAs in TCC lines and normal
uroepithelial cells. Expression of the indicated TCF mRNAs was
determined in the indicated TCC lines, NUEC and HepG2 hepatoma
cells by RT–PCR using GAPDH for comparison (except for hLEF1 and
hTCF3 yielding similar size PCR products as GAPDH). Control refers to
PCR without cDNA, the size marker is shown on the right-hand lane. Note
the double band for hLEF1 corresponding to known splice variants and the
additional band for hAES in NUEC, which may be a novel splice variant.
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set al, 1993). While four TCC lines, as well as normal urothelial cells
and HepG2 showed hTCF3 expression, only weak expression could
be detected in SD and HT1376, and also a very faint band in the
inducible cell line SW1710 (Figure 3C). Neither hLEF1 nor hTCF3
expression patterns correlated with inducibility among the TCC
lines. Since other Grg/TLE factors have been described as
ubiquitous (Brantjes et al, 2001), we investigated only hAES
mRNA by RT–PCR, which is the only member in the Grg/TLE-
family that is not a repressor. Figure 3E demonstrates that hAES
was expressed in all TCC lines, normal urothelial cells and HepG2,
except for BFTC905 showing only weak expression. In normal
urothelial cells, a second faint band could be observed, which may
correspond to a splice variant. As for hTCF1, both inducible TCC
lines displayed slightly increased hAES expression relative to
GAPDH.
Role of E-cadherin
Since E-cadherin has been reported to act as an inhibitor of b-
catenin/TCF-mediated transcription by sequestering b-catenin at
the plasma membrane (Stockinger et al, 2001) and loss of E-
cadherin to be frequent in TCC (Rieger et al, 1995), the differences
in WNT/b-catenin signalling between the TCC lines could be
related to E-cadherin expression. Indeed, the CDH1 gene encoding
E-cadherin was found to be hypermethylated in SW1710 (Table 1).
In Western blot analysis, the TCC lines VMCub1, SD, HT1376 and
BFTC905 as well as normal urothelial cells were found to express
E-cadherin (Figure 4A). Diminished expression or loss of E-
cadherin protein was observed in both inducible TCC lines,
SW1710 and 5637, and in the noninducible VMCub2 line. We
therefore tested whether re-expression of E-cadherin in the
inducible TCC lines SW1710 and 5637 might restore repression
of b-catenin/TCF signalling in reporter gene analysis. In both cell
lines, significant inhibition of promoter activation by b-catenin
was elicited by E-cadherin cotransfection (Figure 4B). In SW1710
and 5637, induced levels of pTOPluc promoter activity were
diminished by 60 and 90%, respectively. Smaller effects were
observed on pFOPluc.
APC expression
In addition to methylation analysis of the APC gene, its expression
was investigated at the protein level by Western blot analysis. APC
protein was present in all TCC lines and normal urothelial cells
and even detectable in HepG2 cells, albeit at a lower level. In
particular, diminished levels were neither observed in the TCC
lines SW1710 and 5637, which were inducible by b-catenin, nor in
HT1376 cells, which displayed hypermethylation of all APC alleles
(data not shown).
DISCUSSION
Constitutive activity of the WNT/b-catenin signalling pathway is
an important step in the development of many human cancers.
However, none of the typical mutations in components of this
pathway have been reported in TCC. Few studies have appeared
addressing this issue explicitly, which is likely due to publication
bias against negative results (Stoehr et al, 2002). Still, a lack of
mutations in known components of a pathway does not permit the
conclusion that it is intact unless its actual functional state has
been determined. This is difficult to perform in TCC tissues, but
can be done by reporter gene analysis in TCC lines that show the
typical genetic aberrations of advanced bladder cancers. The
results of the present study are in accord with the impression from
the literature that activating mutations in the WNT/b-catenin
signalling pathway are rare or absent in TCC. Moreover, the data
suggest that this pathway is inactive in and not required for
proliferation of TCC cells. Since the same result was obtained with
proliferating NUEC, the lack of basal activity in TCC cells is likely
an extension of the state in the normal tissue. Moreover, even in
normal cells, the pathway could not be activated by oncogenically
activated b-catenin. Thus, the WNT/b-catenin signalling pathway
is not only inactive, but turned off in urothelial cells, likely because
it is not required for proliferation and perhaps to avoid
inappropriate target gene activation. More speculatively, it is
interesting to consider the downregulation of the WNT/b-catenin
pathway in urothelial cells and carcinomas in the light of current
hypotheses on the function of the pathway in maintaining stem cell
properties (Taipale and Beachy, 2001). According to our data, such
a function in uroepithelial tissue seems unlikely. This might be
related to its particular organisation as a transitional epithelium
with its low turnover, in which stem cells may behave differently as
in colon.
Nevertheless, the activation of typical WNT/b-catenin target
genes such as CCND1 and MYC is required for the proliferation of
uroepithelial cells, too. Proliferation of NUEC is stimulated by
growth factors such as EGF and, in an autocrine fashion, HB-EGF
(Freeman et al, 1997). Since these factors act via MAPK signalling
(Swiatkowski et al, 2002), they seem quite sufficient to stimulate
the necessary transcription of CCND1 and MYC in an alternative
fashion to WNT/b-catenin signalling. Almost all advanced TCC
display defects in either RB1 or CDKN2A, which obliterate the
requirement for cyclin D1 (cf. Table 1). Furthermore, in some
cases CCND1 itself is amplified (Proctor et al, 1991). Increased
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Figure 4 Expression and function of E-cadherin. (A) Expression of E-
cadherin was determined in the indicated TCC lines and in NUEC by
Western blotting (B) using a-tubulin for comparison. Control refers to a
lysate from cells transfected with an E-cadherin expression construct. (B)
Effect of E-cadherin cotransfection on induction of pTopFlash reporter
activity by oncogenic b-catenin in the TCC lines SW1710 and 5637. Values
are mean7s.d. of the relative activity of pTopFlash or pFopFlash (as
indicated) without any cotransfection (white bars), with transfected pbcat
only (grey bars) or pbcat and pEGFP-UM expressing E-cadherin (dark bars).
Activity of LINEluc was set as 100%. The differences in pTOP-Flash
activation caused by E-cadherin cotransfection are statistically significant (t-
test: Po0.05) in both cell lines.
WNT signalling in urothelial cells
I Thievessen et al
1936
British Journal of Cancer (2003) 88(12), 1932–1938 & 2003 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sexpression of MYC is found in almost all TCC, and is correlated
with increased gene copy numbers (Christoph et al, 1999) and/or
overexpression of the EGF receptor (Lipponen, 1995). Thus,
upregulation of MYC or CCND1, required for the proliferation of
TCC cells, is likely achieved by mechanisms other than activation
of WNT/b-catenin signalling.
This interpretation implies that the inducibility of TCF-
dependent gene expression found in the TCC lines 5637 and
SW1710 is a deviation from the normal state in the urothelium and
that at least one of the mechanisms ensuring inactivity of the
WNT/b-catenin pathway has become defective. We did not observe
significant differences between these two cell lines and the others
in expression of overall b-catenin, hLEF1, hTCF3 and hTCF4.
However, both cell lines displayed decreased expression of E-
cadherin. Indeed, restoration of E-cadherin expression caused
repression of TCF/b-catenin-induced transcriptional activity
(Figure 4B). On a note of caution, our data indicate that E-
cadherin expression cannot be the only factor determining
inducibility of WNT/b-catenin signalling, since VMCub2 cells also
lacked the protein, but did not respond to b-catenin transfection.
Interestingly, both inducible TCC lines, but not VMCub2,
displayed slightly increased mRNA expression of hTCF1 and
hAES. If hTCF1 acts as a feedback repressor of b-catenin/TCF4
signalling (Roose et al, 1999), increased hTCF1 expression in
SW1710 and 5637 obviously cannot account for their inducibility
by b-catenin. However, the hAES homologue Grg5 is known to act
as a de-repressor of TCF-mediated transcription (Roose et al,
1998). Thus, in addition to E-cadherin loss increased hAES levels
could contribute to inducibility of b-catenin/TCF signalling in
SW1710 and 5637. The potential roles of hTCF1 and hAES are
more difficult to address experimentally than that of E-cadherin,
since the differences in hTCF1 and hAES expression between the
cell lines were only quantitative.
The finding that E-cadherin modulates WNT/b-catenin signal-
ling in urothelial cells is in line with recent data suggesting this as a
function of E-cadherin additional to or coordinate with mediating
cell adhesion (Stockinger et al, 2001). In this regard, our findings
suggest that while constitutive activation by ‘classical’ mutations
does not occur, the WNT/b-catenin pathway may play a certain
role in a subset of TCC, likely those with loss of E-cadherin
expression. This subset of tumours may show increased sensitivity
towards WNT factors present in the tissue. Indeed, changes in
WNT7B expression have been reported in some TCC (Bui et al,
1998). Loss of E-cadherin expression in TCC is associated with a
worse clinical prognosis (Bornman et al, 2001). It might be
worthwhile to investigate the emerging connection between WNT
expression, E-cadherin loss and clinical prognosis in more detail.
Finally, hypermethylation of the CDH1 and APC genes has been
reported in TCC tissues. Hypermethylation of CDH1 was found to
be associated with loss of protein expression, although not all cases
with loss of protein also displayed hypermethylation (Bornman
et al, 2001; Ribeiro-Filho et al, 2002). This was reflected in the TCC
cell lines investigated here. Downregulation of E-cadherin expres-
sion was found in 3/7 cell lines, but hypermethylation in only one.
While the significance of CDH1 hypermethylation is thus likely,
that of APC hypermethylation, reported at frequencies up to 30%
(Maruyama et al, 2001), is not obvious in TCC. The HT1376 cell
line showed methylation of all APC alleles, but neither basal
activity nor inducibility of the WNT/b-catenin pathway were
observed. In fact, APC protein expression could be detected in
HT1376. While this suggests that APC hypermethylation does not
implicate activation of WNT/b-catenin signalling, more extensive
studies are required on this issue.
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